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ABSTRACT
Objective: In the 1997 TNM staging system, tumors were classified into a single subdivision: T2a, and bilateral tumor
involvement (T2b). In the 2002 TNM staging system, tumors are subclassified as T2a (less than one half of one lobe
involvement), T2b (more than one half of one lobe involvement), and T2c (bilateral involvement). A recent study ques-
tioned the existence of a true pathologic pT2b tumor. The aim of our study is to verify this question.
Materials and Methods: The study population consisted of 224 men submitted to radical retropubic prostatectomy. The
surgical specimens were histologically evaluated by complete embedding and whole-mount processing. Tumor extent was
evaluated by a point-count method. The surgical specimens were staged according to the 2002 TNM staging system.
Results: Using the 2002 TNM criteria, the surgical specimens were classified as pT2a, 28 (12.50%); pT2b, 0 (0%); pT2c,
138 (61.61%); pT3a, 30 (13.39%); and, pT3b, 28 (12.50%). Using the point-count method for tumor extent evaluation, the
minimum and maximum total points obtained in unilateral tumors were 192 and 368 points, respectively; the most exten-
sive unilateral tumor showed 68 positive points (less than half the minimum total point-count).
Conclusions: Using the point-count method for tumor extent, our study questions a real existence for pathologic stage pT2b
tumors (unilateral tumors involving greater than one-half of one lobe).
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INTRODUCTION
In the 1997 TNM staging system, unilateral
disease was combined into a single subdivision, T2a,
and bilateral tumor involvement as T2b (1). In the
2002 TNM staging system (2) tumors were subclas-
sified as T2a (one half of one lobe involvement or
less), T2b (more than half of one lobe involvement,
but not both lobes), and T2c (involvement of both
lobes). A recent study questioned the existence of a
true pathologic pT2b tumor (3). The purpose of our
study is to check this question.
MATERIALS AND METHODS
The study was done on 224 consecutive pa-
tients submitted to radical retropubic prostatectomy
from January 1997 to June 2005 in our Institution.
The clinicopathologic variables studied were age,
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preoperative PSA, prostate weight, Gleason score,
tumor extent, extraprostatic extension, seminal vesicle
invasion, and surgical margins.
The surgical specimen previously fixed was
weighed, measured and the entire surface inked. The
bladder neck and apical margins were amputated.
From each cone-shaped amputated margins, 8 frag-
ments were processed through perpendicular sections
relative to the margins. The rest of the prostate was
serially cut in transverse sections at 3 to 5mm inter-
vals. The prostate slices were subdivided into quad-
rants and labeled to allow reconstruction as whole-
mount sections.
Blocks were embedded in paraffin, cut at
6µm, and one section from each block was stained
with hematoxylin and eosin. Presence of adenocarci-
noma was diagnosed according to the criteria of
Mostofi and Price (4). Histological grading was per-
formed according to the Gleason system (5,6). Semi-
nal vesicle invasion was defined as invasion of the
muscular wall as described by Epstein et al. (7), and
extraprostatic extension was diagnosed according to
Bostwick & Montironi (8) whenever cancer was seen
in adipose tissue. Positive surgical margins (bladder,
apical or circumferential) were defined as cancer cells
touching the inked surface of the prostate.
Tumor extent was estimated by use of a point-
count method (9,10). Drawn on a sheet of paper, each
quadrant of the whole-mount sections contained 8
equidistant points. During the microscopic examina-
tion of the slides, the tumor area was drawn on the
correspondent quadrant seen on the paper. At the end
of the examination, the amount of positive points rep-
resented an estimate of tumor extent (Figure-1).
RESULTS
Table-1 shows the whole-mount surgical
specimens characteristics of 224 patients serially sub-
mitted to retropubic prostatectomy. The mean age was
63.35 years (range, 43-76 years); mean preoperative
PSA 10.23 ng/mL (range, 0.28-50); and, mean pros-
tate weight 39.36g (range, 15-130g). Using the 2002
TNM pathologic classification, 28 specimens were
pT2a (12.50%); 138, pT2c (61.61%); 30, pT3a
Figure 1 – Point-count method for tumor extent evaluation. Trans-
verse whole section of a prostate with a total of 32 points. Tumor
extent corresponds to 4 positive points in the lower-right quad-
rant.
Table 1 –  Patient and tumor characteristics.
Characteristics          N (%)
Mean age in years (range) 063.35 (43 - 76)
Mean preoperative PSA ng/mL (range) 010.23 (0.28 - 50)
Mean prostate weight in grams (range) 039.36 (15 - 130)
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(13.39%); and, 28, pT3b (12.50%) pathologic stages.
No specimen pathologic pT2b stage was found. In 87
(38.84%), 124 (55.36%), and 13 (5.80%) specimens,
the Gleason score was 4-6, 7 and 8-10, respectively.
Extraprostatic extension was found in 55 (24.55%);
seminal vesicle invasion in 28 (12.50%), and posi-
tive surgical margins in 92 (41.07%) surgical speci-
mens.
The results in pathologic stage pT2 unilat-
eral tumors using the point-count method for extent
evaluation are shown in Table-2. The mean and me-
dian of the total points were 289.33 and 300 points,
respectively (range 192-368 points). The mean and
median of the positive points were 9.75 and 5.5 points,
respectively (range 1-68 points). The most extensive
unilateral tumor showed 68 points, therefore less than
half the minimum total point-count.
COMMENTS
In the fifth edition of the TNM classification
of malignant tumors in 1997 (1), stage T2 of prostate
carcinoma was subdivided into T2a (tumor involv-
ing one lobe) and T2b (tumor involving both lobes).
In the sixth edition of 2002 (2), unilateral tumors were
subclassified into T2a (one half of one lobe involve-
ment or less), and T2b (more than half of one lobe
involvement, but not both lobes).
Eichelberger & Cheng (3) question the ex-
istence of a true pathologic stage pT2b tumor. They
studied 369 prostate cancer patients treated by radi-
cal prostatectomy. Prostate cancers were multifocal
in 312 cases (85%). The majority of the specimens
were pathologic stage pT2 (276, or 75%). Using the
2002 TNM staging criteria, 54 (15%) of the tumors
were stage pT2a, 222 (60%) were pT2c, 75 (20%)
were pT3a, and 18 (5%) were pT3b. No pathologic
stage pT2b tumors were identified. Our findings
agree with Eichelberger & Cheng (3). No tumor
pathologic stage pT2b was found and the frequency
of the stages in our series is very similar to theirs:
stage pT2a, 28 (12.50%); pT2c, 138 (61.61%); pT3a,
30 (13.39%); and, pT3b 28 (12.50%). A higher num-
ber of cases in stage pT3b in our series probably is
due to selection of patients with high level of serum
Table 2  – Total and positive points obtained in pathologic
stage pT2 unilateral tumors using the point-count method
for extent evaluation.
  Total Points Positive Points




PSA submitted to prostatectomy in 1997 and 1998.
The mean preoperative PSA was 8.4 and 10.23ng/
mL, in Eichelberger & Cheng´s (3) and in our se-
ries, respectively.
Based on clinical characteristics there is also
questioning regarding subclassification of stage T2.
Freedland et al. (11) studied 1606 men with organ-
confined disease (pT2NO) who were treated with radi-
cal prostatectomy between 1982 and 2003 by one
surgeon. Using the 1997 TNM staging criteria, clini-
cal characteristics were compared between men with
pT2a and pT2b tumors using rank-sum analysis, and
prostate-specific antigen (PSA) recurrence data were
compared using log-rank analysis. There was no dif-
ference in PSA recurrence rates between men with
pT2aNO versus pT2bNO tumors. Rubin et al. (12)
reported the results of 1613 consecutive radical pros-
tatectomy cases conducted from 1994 to 2002 with
up to 8 years of clinical follow-up. In this report, the
authors concluded that the 1997-2002 AJCC recom-
mendation that unilateral organ-confined tumors
(pT2a) be separate category from bilateral (pT2b)
should be eliminated as there was no significant re-
currence-free survival between these pT2a and pT2b
categories.
The present study evaluated unilateral patho-
logic stage pT2 tumors using a point-count method
for tumor extent evaluation (9,10) that is superior to
the visual estimate used by Eichelberger and Cheng
(3). Tumor volume can accurately be calculated us-
ing computer-assisted image analysis systems. Be-
cause this method is not feasible for routine clinical
practice, other investigators have proposed alterna-
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tive simpler means of measuring tumor volume in-
cluding diameter of largest tumor focus, number of
tumor foci, number of involved blocks, percentage
of blocks involved, use of a grid with 3.0 mm squares,
or naked eye examination of the glass slides after the
pathologist had circled all microscopically identifi-
able foci of carcinoma with a marking pen (the
pathologist’s percentage estimate) (13-18).
The method for evaluating tumor extent ap-
plied in this study is a simple one and accessible to
all general pathologists (9,10). It does not need any
special device except a drawing on a sheet of paper.
It is not time consuming because the pathologist draws
on a sheet of paper the proportional area seen on the
microscopic field at the same time he examines the
slides. Considering that only a visual estimate of tu-
mor extent provides important prognostic informa-
tion after radical prostatectomy (14), the procedure
used in this study seems to be superior because it in-
cludes a semi-quantitative point-count method repre-
sented by 8 equidistant points in each quadrant of the
whole-mount transverse sections.
CONCLUSIONS
Using the 2002 TNM staging system, the ma-
jority of the totally embedded, serially sectioned,
whole-mount surgical specimens of patients submit-
ted to retropubic prostatectomy were pathologic stage
pT2, however no stage pT2b tumors were identified
(unilateral tumors that extended to more than half the
area using a point-count method for tumor extent
evaluation). Our results question the existence of a
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